Edan Instruments

Edan Instruments Equity Growth

The Year-over-Year Equity Growth of Edan Instruments (300206.SZ) as of Oct 27, 2026 is 9.18 %. In the previous year, Year-over-Year Equity Growth was 2.20 % — a change of 317.90% (higher).

Equity Growth

9.18 %

YoY

317.90%

Last updated:

Year-over-Year Equity Growth of Edan Instruments is 2025 9.18 % . Year-over-Year Equity Growth of Edan Instruments was 2024 2.20 % . It decreases by 317.90% higher compared to the previous year.

The Edan Instruments Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
0.93 CNY
Jan 1, 2019
3.63 CNY
Jan 1, 2020
40.28 CNY
Jan 1, 2021
-4.31 CNY
Jan 1, 2022
6.93 CNY
Jan 1, 2023
6.06 CNY
Jan 1, 2024
2.20 CNY
Jan 1, 2025
9.18 CNY
The Edan Instruments Equity Growth history
YEAREquity GrowthYoY
9.18 %+317.90%
2.20 %-63.75%
6.06 %-12.67%
6.93 %-260.95%
-4.31 %-110.70%
40.28 %+1,008.94%
3.63 %+289.76%
0.93 %-64.59%
2.63 %+88.28%
1.40 %-33.19%
2.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Edan Instruments Stock analysis

What does Edan Instruments do? Edan Instruments, Inc. generates revenue through the design, manufacture, and sale of medical equipment, including maternity product series like doppler fetal heart beat monitors, ultrasonic doppler fetal heart beat monitors, fetal/maternal monitors, and maternity integrated diagnostic monitoring systems. The company also sells electrocardiograph series such as digital twelve-channel electrocardiographs, digital six-channel electrocardiographs, and electrocardiographic workstations, along with monitoring products like portable multi-variable monitors and central monitoring systems. Additionally, Edan offers spare parts and in vitro diagnostics products to support its equipment and medical services. The primary buyers of Edan's products are healthcare institutions, including hospitals and clinics, which purchase medical devices for diagnostic and monitoring purposes. These institutions rely on Edan's maternity, electrocardiograph, and monitoring systems to provide patient care. The company's in vitro diagnostics products are also sold to medical facilities for laboratory testing needs. Edan's product segments are defined by medical equipment categories: maternity, electrocardiograph, monitoring, and ultrasonic image systems. The spare parts and in vitro diagnostics businesses complement these segments by providing essential accessories and diagnostic tools. Revenue is derived from direct sales of these products to healthcare providers, with no mention of third-party distribution or additional services beyond the described offerings. Edan Instruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Edan Instruments stock

Year-over-Year Equity Growth of Edan Instruments is 9.18 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Edan Instruments since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Edan Instruments historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Edan Instruments

All Key Metrics — Edan Instruments